ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
The role of absent in melanoma 2 (AIM2) in cardiovascular diseases.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cardiovascular diseases (CVDs) are a group of conditions that significantly affect human health and are among the leading causes of death and disability worldwide. Clinical trials and basic research have demonstrated that inflammation plays a pivotal role in the development of CVDs. The inflammasome is a critical component of the innate immune system, involved in various inflammatory responses to pathogens and tissue damage. Absent in melanoma2(AIM2), which belongs to the PYHIN Family, is a receptor for intracellular DNA pattern recognition. AIM2 inflammasomes are implicated in the onset and progression of CVDs, activated in atherosclerotic plaques, aortic aneurysms, and damaged myocardium. This review summarizes recent advances in AIM2 research in CVDs, exploring its interactions with other inflammasomes and emphasizing its central role in immune and inflammatory responses. Specifically, the review summarizes the progress of AIM2 inhibitors, in order to critically evaluate the translational potential of such concepts into clinical practices.
Indexed as
Identifiers
40928565What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.